Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ARTC's Cash to Debt is ranked higher than
99% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. ARTC: No Debt )
ARTC' s 10-Year Cash to Debt Range
Min: 0.47   Max: No Debt
Current: No Debt

Equity to Asset 0.87
ARTC's Equity to Asset is ranked higher than
93% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ARTC: 0.87 )
ARTC' s 10-Year Equity to Asset Range
Min: 0.58   Max: 0.96
Current: 0.87

0.58
0.96
Interest Coverage No Debt
ARTC's Interest Coverage is ranked higher than
78% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. ARTC: No Debt )
ARTC' s 10-Year Interest Coverage Range
Min: 16.19   Max: 9999.99
Current: No Debt

16.19
9999.99
F-Score: 4
Z-Score: 15.27
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.26
ARTC's Operating margin (%) is ranked higher than
76% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. ARTC: 7.26 )
ARTC' s 10-Year Operating margin (%) Range
Min: -153.33   Max: 17.41
Current: 7.26

-153.33
17.41
Net-margin (%) 5.52
ARTC's Net-margin (%) is ranked higher than
75% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. ARTC: 5.52 )
ARTC' s 10-Year Net-margin (%) Range
Min: -128.33   Max: 17.07
Current: 5.52

-128.33
17.07
ROE (%) 5.17
ARTC's ROE (%) is ranked higher than
72% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. ARTC: 5.17 )
ARTC' s 10-Year ROE (%) Range
Min: -28.36   Max: 13.83
Current: 5.17

-28.36
13.83
ROA (%) 3.76
ARTC's ROA (%) is ranked higher than
74% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. ARTC: 3.76 )
ARTC' s 10-Year ROA (%) Range
Min: -25.67   Max: 10.47
Current: 3.76

-25.67
10.47
ROC (Joel Greenblatt) (%) 31.52
ARTC's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. ARTC: 31.52 )
ARTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -134.81   Max: 92.74
Current: 31.52

-134.81
92.74
Revenue Growth (%) 0.10
ARTC's Revenue Growth (%) is ranked higher than
64% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ARTC: 0.10 )
ARTC' s 10-Year Revenue Growth (%) Range
Min: 0.1   Max: 87.7
Current: 0.1

0.1
87.7
EBITDA Growth (%) -15.80
ARTC's EBITDA Growth (%) is ranked higher than
62% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. ARTC: -15.80 )
ARTC' s 10-Year EBITDA Growth (%) Range
Min: -26.4   Max: 64.2
Current: -15.8

-26.4
64.2
EPS Growth (%) -14.70
ARTC's EPS Growth (%) is ranked higher than
65% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ARTC: -14.70 )
ARTC' s 10-Year EPS Growth (%) Range
Min: -44.1   Max: 272.1
Current: -14.7

-44.1
272.1
» ARTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ARTC Guru Trades in Q3 2013

Joel Greenblatt 98,823 sh (+407.67%)
Jim Simons 593,600 sh (+11.08%)
Mario Gabelli 334,000 sh (-0.18%)
Paul Tudor Jones 125,000 sh (-2.8%)
Steven Cohen 117,412 sh (-84.32%)
» More
Q4 2013

ARTC Guru Trades in Q4 2013

Steven Cohen 290,275 sh (+147.23%)
Paul Tudor Jones 186,395 sh (+49.12%)
Jim Simons 789,400 sh (+32.99%)
Joel Greenblatt Sold Out
Mario Gabelli 325,300 sh (-2.6%)
» More
Q1 2014

ARTC Guru Trades in Q1 2014

John Paulson 2,000,000 sh (New)
Jim Simons 1,161,901 sh (+47.19%)
Mario Gabelli 465,656 sh (+43.15%)
Steven Cohen Sold Out
Paul Tudor Jones 6,357 sh (-96.59%)
» More
Q2 2014

ARTC Guru Trades in Q2 2014

John Paulson Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 Sold Out 0.47%$48.13 - $48.63 $ 48.590%0
Mario Gabelli 2014-06-30 Sold Out 0.12%$48.13 - $48.63 $ 48.590%0
John Paulson 2014-03-31 New Buy0.47%$39.32 - $49.56 $ 48.593%2000000
Mario Gabelli 2014-03-31 Add 43.15%0.04%$39.32 - $49.56 $ 48.593%465656
Joel Greenblatt 2013-12-31 Sold Out 0.11%$34.49 - $40.03 $ 48.5931%0
Joel Greenblatt 2013-09-30 Add 407.67%0.09%$31.67 - $37.37 $ 48.5939%98823
Joel Greenblatt 2013-06-30 Reduce -48.93%0.03%$33.03 - $36.19 $ 48.5941%19466
Joel Greenblatt 2013-03-31 Add 96.91%0.03%$34.59 - $36.88 $ 48.5936%38119
Joel Greenblatt 2012-12-31 Reduce -47.09%0.04%$29.73 - $34.09 $ 48.5950%19359
Joel Greenblatt 2012-09-30 Reduce -50.25%0.08%$27.35 - $32.4 $ 48.5963%36588
George Soros 2012-09-30 Sold Out 0.02%$27.35 - $32.4 $ 48.5963%0
Joel Greenblatt 2012-03-31 Add 58.88%0.06%$24.74 - $32.52 $ 48.5984%72128
George Soros 2012-03-31 Reduce -31.46%0.03%$24.74 - $32.52 $ 48.5984%50000
Joel Greenblatt 2011-12-31 Add 24.38%0.03%$25.56 - $31.84 $ 48.5966%45398
Joel Greenblatt 2011-09-30 Add 101.04%0.09%$27.98 - $34.77 $ 48.5953%36498
George Soros 2011-09-30 Reduce -45.16%0.03%$27.98 - $34.77 $ 48.5953%77052
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on ArthroCare Corp

Mario Gabelli Comments on ArthroCare Corp - Apr 30, 2014

ArthroCare Corp. (ARTC) (0.3% of net assets as of March 31, 2014) (ARTC - $48.19 - NASDAQ) is a Texas based developer of medical devices for surgical applications in the orthopedic and ENT fields. On February 3, 2014, the company entered into a $48.25 cash per share merger with UK-based competitor Smith & Nephew plc, valuing the company at $1.5 billion. In addition to the merger consideration, shareholders will likely receive a pro-rata share of the proceeds from a Class Action settlement with Smith & Nephew totaling up to $12 million. The deal has been cleared by antitrust authorities in the U.S. and Germany and is currently being reviewed in the UK. ArthroCare shareholders will vote on the transaction in May and closing is expected by mid-2014.

From Mario Gabelli (Trades, Portfolio)'s first quarter 2014 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about ArthroCare Corp

Mario Gabelli Comments on ArthroCare Corp
ArthroCare Corp. (ARTC) (0.3% of net assets as of March 31, 2014) (ARTC - $48.19 - NASDAQ) is a Texas based developer of medical devices for surgical applications in the orthopedic and ENT fields. On February 3, 2014, the company entered into a $48.25 cash per share merger with UK-based competitor Smith & Nephew plc, valuing the company at $1.5 billion. In addition to the merger consideration, shareholders will likely receive a pro-rata share of the proceeds from a Class Action settlement with Smith & Nephew totaling up to $12 million. The deal has been cleared by antitrust authorities in the U.S. and Germany and is currently being reviewed in the UK. ArthroCare shareholders will vote on the transaction in May and closing is expected by mid-2014. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 106.60
ARTC's P/E(ttm) is ranked higher than
69% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 51.90 vs. ARTC: 106.60 )
ARTC' s 10-Year P/E(ttm) Range
Min: 22.25   Max: 525.63
Current: 106.6

22.25
525.63
P/B 3.36
ARTC's P/B is ranked higher than
68% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. ARTC: 3.36 )
ARTC' s 10-Year P/B Range
Min: 0.37   Max: 5.13
Current: 3.36

0.37
5.13
P/S 3.78
ARTC's P/S is ranked higher than
64% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ARTC: 3.78 )
ARTC' s 10-Year P/S Range
Min: 0.28   Max: 5.89
Current: 3.78

0.28
5.89
PFCF 2429.50
ARTC's PFCF is ranked higher than
74% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 623.33 vs. ARTC: 2429.50 )
ARTC' s 10-Year PFCF Range
Min: 5.79   Max: 2430.5
Current: 2429.5

5.79
2430.5
EV-to-EBIT 53.65
ARTC's EV-to-EBIT is ranked higher than
71% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 35.69 vs. ARTC: 53.65 )
ARTC' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 69.3
Current: 53.65

9.8
69.3
PEG 7.08
ARTC's PEG is ranked higher than
90% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ARTC: 7.08 )
ARTC' s 10-Year PEG Range
Min: 1.62   Max: 4.17
Current: 7.08

1.62
4.17
Shiller P/E 16080.53
ARTC's Shiller P/E is ranked lower than
59% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ARTC: 16080.53 )
ARTC' s 10-Year Shiller P/E Range
Min: 59.45   Max: 990.6
Current: 16080.53

59.45
990.6
Current Ratio 5.87
ARTC's Current Ratio is ranked higher than
90% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ARTC: 5.87 )
ARTC' s 10-Year Current Ratio Range
Min: 1.31   Max: 23.57
Current: 5.87

1.31
23.57
Quick Ratio 4.95
ARTC's Quick Ratio is ranked higher than
89% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. ARTC: 4.95 )
ARTC' s 10-Year Quick Ratio Range
Min: 0.87   Max: 22.64
Current: 4.95

0.87
22.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.25
ARTC's Price/Net Cash is ranked higher than
90% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ARTC: 14.25 )
ARTC' s 10-Year Price/Net Cash Range
Min: 3.58   Max: 210.1
Current: 14.25

3.58
210.1
Price/Net Current Asset Value 9.29
ARTC's Price/Net Current Asset Value is ranked higher than
86% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ARTC: 9.29 )
ARTC' s 10-Year Price/Net Current Asset Value Range
Min: 3.29   Max: 291.45
Current: 9.29

3.29
291.45
Price/Tangible Book 5.27
ARTC's Price/Tangible Book is ranked higher than
70% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. ARTC: 5.27 )
ARTC' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 20.23
Current: 5.27

1.25
20.23
Price/DCF (Projected) 2.45
ARTC's Price/DCF (Projected) is ranked higher than
82% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 28.89 vs. ARTC: 2.45 )
ARTC' s 10-Year Price/DCF (Projected) Range
Min: 0.32   Max: 16.26
Current: 2.45

0.32
16.26
Price/Median PS Value 1.33
ARTC's Price/Median PS Value is ranked higher than
61% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ARTC: 1.33 )
ARTC' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 6.22
Current: 1.33

0.14
6.22
Price/Graham Number 4.32
ARTC's Price/Graham Number is ranked higher than
74% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 6.95 vs. ARTC: 4.32 )
ARTC' s 10-Year Price/Graham Number Range
Min: 1.5   Max: 17.37
Current: 4.32

1.5
17.37
Earnings Yield (Greenblatt) 1.90
ARTC's Earnings Yield (Greenblatt) is ranked higher than
57% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ARTC: 1.90 )
ARTC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.2
Current: 1.9

1.4
10.2
Forward Rate of Return (Yacktman) 1.99
ARTC's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. ARTC: 1.99 )
ARTC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.7   Max: 32.5
Current: 1.99

-0.7
32.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BQK.Germany
ArthroCare was incorporated in California in 1993 and reincorporated in Delaware in 1995. The Company is a multi-business medical device Company that develops, manufactures and markets minimally invasive surgical products, many of which are based on its patented Coblation(r) technology. The Company has grown well beyond its roots in arthroscopy to capitalize on numerous market opportunities across several medical specialties, improving many existing soft-tissue surgical procedures and enabling new minimally invasive procedures. With its innovative technologies, the Company is improving the lives of individuals suffering from conditions as diverse as torn rotator cuffs and anterior cruciate ligaments to herniated discs and enlarged tonsils/tonsillitis. The Company currently markets minimally invasive surgical products across three core business units-ArthroCare Sports Medicine, which include shoulder and knee arthroscopic products; ArthroCare Spine, which include spinal and neurosurgery products; and ArthroCare Ear, Nose and Throat, which include ear, nose, throat and the Visage(r) cosmetic products; - but also has developed, manufactured and marketed Coblation-based and complementary products for application in neurology, cosmetic surgery, urology and gynecology, with research continuing in additional areas. In each of its core business units, the Company is focusing on driving the application of enabling technologies, primarily for plasma-based soft tissue removal, and increasing the number of minimally invasive procedures being performed. The Company is marketing and selling its arthroscopic/sports medicine, spinal surgery, ENT and cosmetic surgery products using a combination of distributors supported by regional sales mangers, a direct sales force and corporate partners to sell its products both domestically and internationally. The Company owns over 170 issued U.S. patents and over 195 issued international patents. The Company's products are considered medical devices and are subject to regulation in the United States, with the approval of FDA for each of its products. Its primary competitors include Medtronic, Inc., Smith & Nephew, Stryker Corporation, Johnson & Johnson, Olympus (through its subsidiary Gyrus) and Arthrex, Inc.
» More Articles for ARTC

Headlines

Articles On GuruFocus.com
Morning Coffee: Real-Time Picks May 30 2014 
Mario Gabelli Comments on ArthroCare Corp Apr 30 2014 
Steven Cohen Significantly Increases in ArthroCare Corp., Almost 300% Dec 03 2012 
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Stryker Corp. (SYK) Dividend Stock Analysis Dec 16 2011 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Comment for Fair Value Calculation Using Discounted Cash Flow Model Dec 08 2009 
Guru Stocks at 52-Week Low: Genzyme Corp, ArthroCare Corp, Ticketmaster. Nov 30 2008 

More From Other Websites
ArthroCare Ex-Chief Baker Gets 20-Year Term for Fraud Aug 29 2014
Health device firm's ex-execs convicted of fraud Jun 03 2014
Health device firm's ex-execs convicted of fraud Jun 03 2014
ARTHROCARE CORP Files SEC form 8-K, Other Events May 29 2014
ArthroCare, Smith & Nephew to close merger no later than May 29 May 21 2014
ARTHROCARE CORP Files SEC form 8-K, Other Events May 21 2014
ARTHROCARE CORP Financials May 09 2014
ArthroCare Q1 Earnings Miss Ests; Revs In Line May 09 2014
ARTHROCARE CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2014
Factbox: M&A frenzy in healthcare sector May 06 2014
M&A frenzy in healthcare sector May 06 2014
ArthroCare Reports First Quarter 2014 Financial Results May 02 2014
ARTHROCARE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 02 2014
Smith & Nephew to Pay $12 Million to End Investor Suits Apr 10 2014
ARTHROCARE CORP Files SEC form 8-K, Other Events Apr 10 2014
M&A and IPOs a Theme for Medical Device Sector in 2014 Mar 24 2014
Continued Improvement in Medical Device End Markets for 2014: A Wall Street Transcript Interview... Mar 24 2014
Wall Street Transcript Interview with Gregory J. Fluet, the CEO of Urologix, Inc. (ULGX) Mar 17 2014
ARTHROCARE CORP Files SEC form 8-K, Other Events Mar 14 2014
U.S./Canada daily earnings hits & misses Feb 13 - 1800 ET Feb 13 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK